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1015-9584/Copyright ª 2014, Asian SuSummary Background: It is well established that severe hypertriglyceridemia can lead to
pancreatitis. At present, medical treatment for patients with severe hypertriglyceridemia
and repeat pancreatitis attacks is not adequate. The aim of this study was to assess the effec-
tiveness of laparoscopic bariatric surgery in these patients.
Methods: A review of 20 morbidly obese patients with severe hypertriglyceridemia (a triglyc-
eride level of >1000 mg/dL) who received laparoscopic bariatric surgery was performed. The
study population comprised 14 males and six females, with an average age of 35.0 years (range
24e52 years), and the mean body mass index was 38.2 kg/m2 (range 25e53 kg/m2). The pre-
operative mean plasma triglyceride level was 1782.7 mg/dL (range 1043e3884 mg/dL). Four
patients had a history of hypertriglyceridemic pancreatitis and 13 patients had associated dia-
betes.
Results: Of the 20 patients, 17 (85%) received gastric bypass, whereas three (15%) received
restrictive-type surgery. Laparoscopic access was used in all of the patients. Hypertriglyceri-
demia in morbidly obese patients was more commonly associated with male sex and a poorly
controlled diabetic state. The mean weight reduction was 25.5% 1 year after surgery, with a
marked improvement in diabetes management. As early as 1 month following surgery, the
plasma mean triglyceride levels had decreased to 254 mg/dL (range 153e519 mg/dL), and this
was further reduced to mean levels of 192 mg/dL (range 73e385 mg/dL) 1 year after surgery.
One patient developed acute pancreatitis during the perioperative period, but none of the pa-
tients suffered an episode of pancreatitis in the follow-up period (from 6 months to 13 years).
Conclusion: Bariatric surgery can be successfully used as a metabolic surgery in severe hyper-
triglyceridemia patients at risk of acute pancreatitis. However, control of triglyceride levels
prior to bariatric surgery is indicated.ng authors declare no conflicts of interest.
Kuo Road, Taoyuan, Taiwan.
w@yahoo.com.tw (W.-J. Lee).
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reserved.1. Introduction
Hypertriglyceridemia (HTG) is an independent risk factor
for atherosclerotic heart disease.1,2 Moreover, patients
with serum triglyceride (TG) levels >1000 mg/dL are at high
risk of acute pancreatitis.3,4 Diet control, statins, nicotinic
acid, and fibric acid derivatives may be used in the treat-
ment of HTG. It has been reported that in patients with
severe HTG-associated pancreatitis, which had been pre-
viously unresponsive to treatment, plasmapheresis had
proved useful, particularly in pregnant individuals.5e8
However, none of these treatments can provide a cure for
patients with severe HTG accompanied by repeated attacks
of pancreatitis.
Metabolic surgery, defined as surgery aimed at anatom-
ical and functional change to treat a metabolic disorder,
has been proposed to overcome this problem.9 Partial ileal
bypass has been reported as an effective treatment for
resolving HTG, and providing a cure for patients with severe
HTG and repeated pancreatitis attacks.10,11 In this study,
the effectiveness of bariatric surgery was evaluated in
morbidly obese patients with severe HTG.2. Materials and methods
2.1. Patient selection and data sources
The Min-Sheng General Hospital institutional review board
approved the present study (MSIRB2011003). We identified
20 patients with severe HTG (serum TG levels >1000 mg/
dL), who had undergone laparoscopic bariatric surgery
during the period 1997 to 2011, by retrospective review of
our prospectively collected bariatric database. The distri-
bution of the plasma TG levels is shown in Table 1, and
patients with severe HTG comprised only 0.6% of all the
bariatric patients. The study group consisted of 14 males
and six females, with a mean age of 35.0 years (range
24e52 years) and a mean body mass index of 38.2 kg/m2
(range 25e53 kg/m2). The mean body weight was 109.8 kg
(range 67e144 kg). Four patients had a history of recurrent
hypertriglyceridemic pancreatitis, and 13 (65%) patients
had associated type 2 diabetes. The clinical characteristicstriglyceride levels in a
(from 1997 to 2011).




42 100.0and follow-up data were collected and compared with
those of other bariatric patients. Insulin resistance was
measured using the Homeostatic Model Assessment (HOMA)
index, which can be calculated as follows: plasma glucose
(mmol/L)  insulin (mU/mL)/22.5.122.2. Operative techniques
Three patients received restrictive-type surgery (two had
vertical banded gastroplasty and one had adjustable gastric
banding), and 17 patients received gastric bypass surgery
(13 underwent a minigastric bypass and 4 had Roux-en-Y
gastric bypass). All procedures were performed using
laparoscopic techniques and have been described else-
where.13e15 The minigastric bypass is a modification of
Mason’s loop gastric bypass with a long lesser-curvature
tube from the antrum to the Angle of His (outer diameter
1e2 cm, volume 60e80 mL). The jejunum is measured
200 cm from the ligament of Treitz and is brought up to the
distal end of the gastric tube in an antecolic position
(Fig. 1).16 The bypass limb in the minigastric bypass
measured 200 cm (biliopancreatic limb), and in the Roux-
en-Y bypass it measured 100 cm in the biliopancreatic
limb and 150 cm in the alimentary limb.2.3. Statistical analysis
All statistical analyses were performed using SPSS version
12.01 (SPSS Inc., Chicago, IL, USA), with baseline compar-
ison made using Chi-square tests and a two-sample t test.
Continuous variables were expressed as the mean (standard
deviation), with differences expressed as the mean (95%Figure 1 Laparoscopic minigastric bypass (LMGB).




In comparison with the other bariatric patients, patients
with severe HTG were predominantly male and were more
associated with having problems managing their diabetes
(Table 2). The severe HTG group had significantly higher
fasting plasma glucose levels than the other patients
(222.2 mg/dL vs. 115.7 mg/dL, p < 0.05), and exhibited
considerably higher mean glycosylated hemoglobin (HbA1C)
levels than the other patients (9.5% vs. 6.2%, p < 0.05). The
severe HTG group was also more linked with hypercholes-
terolemia, increase in liver enzymes, insulin resistance,
and uric acid level increases.
3.2. Weight loss
An average weight reduction of 28.9 kg (25.5% reduction)
was observed in HTG patients 1 year after surgery, with an
accompanying reduction in mean postoperative body mass
index of 23% (reduced to 29.4 kg/m2) being demonstrated
(Table 3). The weight reduction curve was similar between
the HTG group and the other patients (data not shown).
As in different types of surgery, including restrictive and
gastric bypass types, the mean body weight loss 1 year after
surgery was 28.2% and 24.7%, respectively (Table 4).
3.3. Sequential metabolic parameters
Immediately after surgery, the high plasma TG levels
returned to nearly normal values (Fig. 2). The mean totalTable 2 Comparison of the clinical characteristics of patients w
Factor Severe HTG (n Z 20)
Age (y) 35.0  8.1
Sex (M/F) 13/7
Weight (kg) 109.8  22.3
BMI (kg/m2) 38.2  6.8
Waist (cm) 117.7  14.8
TG (mg/dL) 1782.7  769.7
FPG (mg/dL) 222.2  109.2
AST (IU/L) 70.9  95.4
ALT (IU/L) 98.4  118.1
Insulin (IU/L) 30.0  27.2
HbA1C (%) 9.5  3.1
C-peptide (ng/mL) 6.1  3.6
HOMA-IR 17.0  15.3
Cholesterol, total (mg/dL) 298.0  85.9
LDL-C (mg/dL) 73.0  28.0
Uric acid (mg/dL) 8.1  2.3
WBC (k/mL) 8.4  2.0
*p < 0.05.
ALT Z alanine aminotransferase; AST Z aspartate aminotransfera
HbA1C Z glycosylated hemoglobin; HOMA-IR Z Homeostatic Model A
C Z low-density lipoprotein C; TG Z triglycerides; WBC Z white bloplasma TG level 1 year after surgery was 192.1 mg/dL
(89.2% reduction). There was no difference in the mean
postoperative TG level between patients who received a
restrictive-type procedure and those who received gastric
bypass surgery. The reduction in the restrictive-type pro-
cedure was 86.0% (with no significant differences) and
90.0% in the gastric bypass group (Table 4). All the meta-
bolic disorders of the study group still showed a significant
improvement 1 year after surgery (Table 3). The mean
HbA1C decreased from 9.5% to 5.1%. Among the 13 patients
with diabetes, 12 patients had their diabetes in remission
(HbA1C < 6.0%) 1 year after surgery.
3.4. Clinical findings
No patient experienced an episode of pancreatitis during
the follow-up period (from 6 months to 13 years). However,
one patient developed acute pancreatitis during the oper-
ation. This was a 43-year-old male patient receiving a
laparoscopic Roux-en-Y gastric bypass for revision surgery
of a previous vertical banded gastroplasty operation. The
operation was uneventful, but the patient developed acute
pancreatitis and renal shutdown during the operation. He
developed multiorgan failure and required a prolonged stay
in the intensive care unit. The preoperative plasma TG
level in this patient was 2061 mg/dL. Thereafter, we
delayed the bariatric procedure until the TG level was
reduced to <1000 mg/dL in other patients.4. Discussion
This study confirmed that bariatric surgery can be an
excellent management tool for patients with severe HTG
(>1000 mg/dL), particularly in those cases where this is
accompanied by repeated pancreatitis.11 Using currentith severe hypertriglyceridemia.
Others (n Z 3172) p
32.5  9.5 0.146
864/2318 < 0.001*
107.4  25.4 0.430
39.4  7.7 0.531
115.7  17.7 0.502
171.7  117.4 < 0.001*
108.5  44.3 < 0.001*
32.1  30.0 0.007*
46.1  46.1 0.001*
23.1  29.4 0.156
6.1  1.3 < 0.001*
4.4  7.1 0.003*
6.6  11.5 < 0.001*
194.2  38.2 < 0.001*
127.1  33.6 < 0.001*
7.1  2.6 0.045*
13.7  4.8 0.842
se; BMI Z body mass index; FPG Z fasting plasma glucose;
ssessment-Insulin Resistance; HTG Z hypertriglyceridemia; LDL-
od cell count.
Table 3 Change in clinical characteristics 1 year after
surgery.
Factor After surgery Da p
Weight (kg) 82.8  12.0 32.7  11.4 0.005*
BMI (kg/m2) 29.4  3.5 11.8  4.1 0.005*
Waist (cm) 92.6  7.3 25.1  9.1 0.028*
TG (mg/dL) 143.6  65.5 1142.0  177.5 < 0.001*
FPG (mg/dL) 86.5  11.9 135.7  118.4 0.012*
AST (IU/L) 32.3  27.2 38.6  41.0 0.263
ALT (IU/L) 29.1  21.6 69.3  59.7 0.036*
Insulin (IU/L) 4.9  3.5 25.1  24.1 0.043*
HbA1C (%) 5.1  0.4 4.4  3.4 0.028*
C-peptide
(ng/mL)
2.3  1.1 3.8  2.9 0.068




187.0  37.7 111.0  57.5 0.011*
Uric acid
(mg/dL)
7.6  2.2 0.5  1.9 0.237
WBC (k/mL) 7.0  1.3 1.4  2.1 0.042*
* p < 0.05.
ALT Z alanine aminotransferase; AST Z aspartate amino-
transferase; BMI Z body mass index; FPG Z fasting plasma
glucose; HbA1C Z glycosylated hemoglobin; HOMA-
IR Z Homeostatic Model Assessment-Insulin Resistance;
TG Z triglycerides; WBC Z white blood cell count.
a DZ difference between the preoperative and postoperative
value.
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reduction in the preoperative HTG level 1 year after sur-
gery, and this reduction was still observed up to 5 years
after surgery. More importantly, none of the patients
developed pancreatitis after the severe HTG was
controlled. This result strongly supports the use of bariatric
surgery, as a metabolic surgery, in patients with severe
HTG-induced repeated pancreatitis.
HTG is a common clinical problem that can be exacer-
bated by numerous medications and medical conditions,
including obesity and diabetes. However, severe HTG is
rarely seen in morbidly obese patients seeking bariatric
surgery. Buchwald and Schone11 reported a series of six
cases and proposed that different genetic defects may be
responsible for morbid obesity and severe HTG. Here, we
report on a series of 20 cases, which only comprised 0.6% ofTable 4 Change in triglycerides and mean weight loss 1 year a
Type Surgical method (laparoscopy) No. of
patien
Restrictive Vertical banded gastroplasty 2
Adjustable gastric banding 1
Gastric bypass Minigastric bypass 13
Roux-en-Y gastric bypass 4
TG Z triglycerides.the bariatric surgery cohort in this study. Most of the cases
in this series were associated with type 2 diabetes and
there was male predominance. Poorly controlled diabetes
appears to be the most important trigger factor for severe
HTG in morbidly obese patients. The morbid obesity-
related diabetes is usually associated with very high insu-
lin resistance and nonalcoholic steatohepatitis, which in
turn results in elevated liver enzymes in this specific group
of patients.17
Because insulin resistance is the underlying mechanism
of HTG in morbidly obese patients, the dramatic diabetes
treatment effect of bariatric surgery probably plays an
important role in significantly reducing the severe HTG.18,19
It also explains why three patients, who had received
restrictive-type procedures in this study, also showed a very
good reduction in severe HTG. In our cases, both restrictive
and gastric bypass procedures achieved >24% mean weight
reduction 1 year after surgery (Table 4)dwhich means that
the weight loss is more important than the procedure.
Although rarely seen in morbidly obese patients seeking
bariatric surgery, HTG is the next most common cause of
pancreatitis after gallstones and excessive alcohol con-
sumption.3 In up to 7% of all cases of pancreatitis, HTG or
chylomicronemia is the underlying cause.4 The exact
mechanisms underlying HTG-related pancreatitis are un-
clear. Chylomicrons are TG-rich lipoprotein particles,
believed to be responsible for pancreatic inflammation.4
HTG-related pancreatitis rarely occurs if the TG level is
<500 mg/dL, and people with HTG-related pancreatitis
usually have TG levels of >1000 mg/dL. Therefore, long-
term control of plasma TG levels of <500 mg/dL in pa-
tients with severe HTG is essential to reduce their risk of
developing pancreatitis.
Initially, when treating HTG, removal of offending
medications, lifestyle modifications (e.g., diet, exercise,
abstention from alcohol), and use of drugs such as fibrates
and nicotinic acid should be considered.3 The serum TG
response to diet and weight loss is approximately 25%, with
marked variation among patients. The fibrates can reduce
TG levels by up to 50% and daily consumption of up to 3 g of
nicotinic acid (niacin) can lower TG levels by up to 45%.20
However, none of the medical treatments can achieve the
long-term 90% reduction observed with bariatric surgery.
Apheresis is also proposed for serum TG removal, and to
treat or prevent HTG-induced pancreatitis.5e8 One series of
seven patients, with an average TG level of 1406 mg/dL,
reported a 41% decrease in TG levels after one plasma ex-
change session.21 In another case study, TG was lowered










Figure 2 Reduction in serum triglyceride levels after
surgery.
100 S.-Y. Hsu et al.apheresis.22 Nevertheless, the effect of apheresis is tran-
sient, and repeat procedures may be required. In addition,
each course of apheresis will cost approximately US$ 3000,
which is not cost effective for long-term treatment.5
Therefore, the use of bariatric surgery as a metabolic sur-
gery is probably the best option for long-term management
of patients with severe HTG and repeat pancreatitis
attacks.
The first metabolic surgery for hyperlipidemia was a
partial ileal bypass. Performed in 1963, this procedure was
carried out to specifically reduce plasma lipids.10 For
morbidly obese patients with hypercholesterolemia, gastric
obesity surgery with partial ileal bypass was also recom-
mended.11 Initially, these procedures were designed for the
treatment of hypercholesterolemia, but following the suc-
cess in medical treatment, they went out of favor. How-
ever, these procedures may still play an important role in
the treatment of severe HTG, particularly in patients where
this is accompanied by repeated pancreatitis. The majority
of our patients received laparoscopic minigastric bypass as
a metabolic surgery for the treatment of their intractable
HTG. This procedure is very similar to the former partial
ileal bypass procedure.11 In our previous study, this
simplified gastric bypass had proven to be low risk and was
also an effective procedure in comparison with the lapa-
roscopic Roux-en-Y gastric bypass.15
Although bariatric surgery is very effective in the
treatment of severe HTG, surgery itself may be potentially
dangerous in the presence of HTG. HTG-related pancrea-
titis is usually induced in patients who have TG levels
>1000 mg/dL. One of our patients, whose TG level was
2061 mg/dL, had a life-threatening pancreatitis attack
during the operation. Therefore, we recommend that bar-
iatric surgery be performed only after the TG level has been
reduced to <1000 mg/dL. These patients should be
admitted prior to surgery and closely monitored under
fasting conditions, with regular lipid-lowering medications
being administered. Other treatments, such as using insulin
and heparin to enhance lipoprotein lipase activity,23 and
aphresis5e8 may also be considered. Once the TG levels
have been lowered to <1000 mg/dL, metabolic or bariatric
surgery can then be performed. In addition to the major
complication due to pancreatitis, we also had another pa-
tient who had a minor complication of gastric stasis after
the surgery.In conclusion, we report on a series of severe HTG pa-
tients who were effectively treated using bariatric surgery.
Bariatric surgery, as a metabolic surgery, can be success-
fully applied in patients with severe HTG, particularly if it is
accompanied by repeated pancreatitis attacks.References
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